Skip to main content

Table 3 Univariate and multivariate analyses for pathological response in patients treated with neoadjuvant endocrine letrozole

From: Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial

Variable1Pathological response, n (102)Odds ratio (95% CI) univariatep2Odds ratio (95% CI) multivariatep2
YesNo
TILs (%)3 pretreatment  1.20 (0.84–1.72)0.31  
TILs (%)3 posttreatment  0.78 (0.60–1.02)0.07  
TIL change (%)3  0.71 (0.53–0.96)0.020.71 (0.53–0.96)0.02
KI67 index (%)3 pretreatment  0.99 (0.96–1.01)0.22  
Ki67 index (%)3 posttreatment  0.53 (0.31–0.91)0.02  
Age (years)
 60–6934280.81 (0.36–1.81)0.61  
 70–8924161   
Tumour size (mm)0.03  
 < 2031142.46 (1.10–5.57)   
 ≥ 2027301   
Subtype0.03 0.03
 Ductal46261 1 
 Other invasive12180.38 (0.16–0.90) 0.37 (0.15–0.91) 
Malignancy grade0.26  
 122131.07 (0.42–2.66)   
 227171   
 3140.16 (0.02–1.53)   
Axillary node status prior to treatment0.99  
 Negative31241   
 Positive26201.01 (0.46–2.22)   
 Unknown10   
Oestrogen receptor status (%)0.15  
 10–998110.48 (0.18–1.32)   
 10050331   
Progesterone receptor status (%)0.78  
 0–9941320.88 (0.36–2.16)   
 10016111   
 Unknown11   
  1. Data reported as n. 1Unless otherwise specified, variables are pretreatment values. 2Excluding unknowns. 3Continuous variable, per 10% increase
  2. TILs, tumour-infiltrating lymphocytes